Catalyst
Slingshot members are tracking this event:
Top-line results expected Esperion's (ESPR) Phase 2 study (1002-039) of bempedoic acid added-on to a once-monthly injectable PCSK9 inhibitor expected in March 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 27, 2018
Occurred Source:
http://investor.esperion.com/releasedetail.cfm?ReleaseID=1062028
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bempedoic Acid, Phase 2 Trial
